Home / Research library / Liraglutide
Liraglutide: molecular data, studies & sources
Liraglutide is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C172H265N43O51
- Molecular weight (MW)
- 3751 g/mol
- PubChem compound ID
- 16134956
- Record title
- Liraglutide
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 16134956 · retrieved 2026-09-21

Chemical identifiers and source data
- IUPAC name
- (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
- InChIKey
- YSDQQAXHVYUZIW-QCIJIYAXSA-N
- SMILES
- CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O
Human and clinical studies
Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.
- Human study · PubMed trial index
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM, Greenway FL, Khalid U et al. · JAMA · 2022
PMID 35015037 · DOI: 10.1001/jama.2021.23619
- Human study · PubMed trial index
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
Fox CK, Barrientos-Pérez M, Bomberg EM et al. · The New England journal of medicine · 2025
PMID 39258838 · DOI: 10.1056/NEJMoa2407379
- Human study · PubMed trial index
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K et al. · The New England journal of medicine · 2015
PMID 26132939 · DOI: 10.1056/NEJMoa1411892
- Human study · PubMed trial index
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Lundgren JR, Janus C, Jensen SBK et al. · The New England journal of medicine · 2021
PMID 33951361 · DOI: 10.1056/NEJMoa2028198
- Human study · PubMed trial index
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K et al. · The New England journal of medicine · 2016
PMID 27295427 · DOI: 10.1056/NEJMoa1603827
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Preclinical / laboratory research
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
Secher A, Jelsing J, Baquero AF et al. · The Journal of clinical investigation · 2014
PMID 25202980 · DOI: 10.1172/JCI75276
- Preclinical / laboratory research
Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.
Guo T, Yan W, Cui X et al. · Molecular medicine (Cambridge, Mass.) · 2023
PMID 37770820 · DOI: 10.1186/s10020-023-00721-7
Liraglutide supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Compare all Liraglutide sizes, forms and supplier prices →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 5mg Vial1 recorded offers | 5mg Vial · $45.90Checked Sep 16, 2026Supplier listing |
Reference sources & further reading
- PubChem compound record 16134956 — chemical identity and structure.
- Wikipedia: Liraglutide — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Cagrilintide
C194H312N54O59S2
4409 g/mol · PubChem CID 171397054
5 selected publications · 4 human study records
Mazdutide
C207H317N45O65
4476 g/mol · PubChem CID 167312357
6 selected publications · 5 human study records
Retatrutide
C221H342N46O68
4731 g/mol · PubChem CID 171390338
8 selected publications · 6 human study records
Semaglutide
C187H291N45O59
4114 g/mol · PubChem CID 56843331
8 selected publications · 5 human study records
Survodutide
C192H289N47O61
4232 g/mol · PubChem CID 168429725
5 selected publications · 5 human study records
Tirzepatide
C225H348N48O68
4813 g/mol · PubChem CID 156588324
8 selected publications · 7 human study records